FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections Johnson & Johnson Pharmaceutical Research & Development, L.L.C., announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections. [more...]
